Please assess the completion status of the following clinical trial:

Trial Title: Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* must have received primary taxane and platinum-based chemotherapy and no more than 1 other chemotherapy regimen~* must have platinum resistant disease(defined as recurrence within 6 months of receiving platinum based chemotherapy, first or second line)~* must have measurable disease (greater than 20mm by conventional techniques or 10mm by spiral CT) OR elevated CA-125 (\> 100 on two occasions at least one week apart~* performance status greater than or equal to 70%~Exclusion Criteria:~* prior treatment with anti-angiogenesis agent~* treatment with \> 2 cytotoxic regimens (including primary platinum and taxane chemotherapy)~* evidence of other malignancy within 3 years of study enrollment~* history of abdominal fistula, grade 4 bowel obstruction or gastrointestinal perforation~* history of intra-abdominal abscess with 6 months prior to day 0~* pregnant or lactating patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).